Johnson & Johnson moved 0.6% this evening session, trading between a high of $163.925 and a low of $161.53 per share. Yesterday the stock finished at $162.66 per share, compared to an average analyst target price of $180.95.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 2.8%. Johnson & Johnson has trailing twelve months earnings per share (EPS) of 4.93, which at today's prices amounts to a price to earnings (P/E) ratio of 33.2.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 2.82. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-16 | 94,943,000 | -31,089,000 | 67 | -1.47 |
| 2022-02-17 | 93,775,000 | -29,855,000 | 68 | 3.03 |
| 2021-02-22 | 82,584,000 | -28,427,000 | 66 | 0.0 |
| 2020-02-18 | 82,059,000 | -27,556,000 | 66 | -1.49 |
| 2019-02-20 | 81,581,000 | -27,091,000 | 67 | 0.0 |
| 2018-02-21 | 76,450,000 | -25,439,000 | 67 |
Johnson & Johnson's 66.8% average gross margins are thinner than the 60.94% average of the Pharmaceutical industry, implying that the firm might be lacking in competitivity.
